News | October 17, 2006

Excellent Results Reported for CoreValve Device

A test designed to measure the durability of CoreValve’s ReValving device reached 200 million cycles, the company has reported. CoreValve’s chairman, CEO and founder, Dr. Jacques Seguin, says initial findings indicate its proprietary porcine pericardium aortic heart valve behaves, in vitro, better than tissue valves.

The valve is parts of its ReValving System for percutaneous aortic valve replacement (PAVR).

Condensing equivalent years of service life into months of testing, the company indicates it is applying advanced control and data-acquisition methods to monitor valve function and integrity. Testing is being conducted under strictly controlled regulatory guidelines.

"This event represents another mission-critical milestone toward marketing clearance in Europe as well as commencement of clinical trials in the United States," added Rob Michiels, president and COO of CoreValve


Related Content

News | Heart Valve Technology

September 26, 2022 — Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates ...

Home September 26, 2022
Home
News | Heart Valve Technology

September 15, 2022 — Cardiac Implants LLC has announced the successful initial deployment of its Annuloplasty ring with ...

Home September 15, 2022
Home
News | Heart Valve Technology

September 9, 2022 — The U.S. Food and Drug Administration (FDA) is alerting healthcare providers about potential clip ...

Home September 09, 2022
Home
News | Heart Valve Technology

May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) ...

Home May 19, 2022
Home
News | Heart Valve Technology
May 5, 2022 – Foldax, Inc. has announced that the first patients have been enrolled in the Drugs Controller General of ...
Home May 05, 2022
Home
News | Heart Valve Technology

April 27, 2022 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall for the Medtronic Harmony ...

Home April 27, 2022
Home
News | Heart Valve Technology
March 2, 2022 – An international study led by a researcher from Tel Aviv University offers a novel technology that can ...
Home March 02, 2022
Home
News | Heart Valve Technology
February 28, 2022 - Foldax, Inc. has announced the presentation of results from the first animal study of its ...
Home February 28, 2022
Home
News | Heart Valve Technology
February 14, 2022 — SMT (Sahajanand Medical Technologies Limited) has announced the publication of Hydra Transcatheter ...
Home February 14, 2022
Home
News | Heart Valve Technology

December 13, 2021 - Foldax Inc. announced that the Drugs Controller General of India (DCGI), India’s regulatory body for ...

Home December 13, 2021
Home
Subscribe Now